Is altered pain sensation a feature of neurotoxicity in patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Altered Pain Sensation in Neurotoxicity

Yes, altered pain sensation is a hallmark feature of neurotoxicity, manifesting as both heightened pain responses (hyperalgesia, allodynia, dysesthesia) and diminished pain perception (hypoalgesia) depending on the nerve fiber types affected. 1

Characteristic Pain Alterations in Neurotoxicity

"Plus" Symptoms (Heightened Pain Sensation)

Neurotoxicity typically produces neuropathic "plus" features that represent abnormal pain sensations:

  • Acral pain and paresthesia presenting as tingling sensations ("pins and needles") in hands and feet 1
  • Dysesthesia - unpleasant abnormal sensations triggered by normal stimuli 1
  • Allodynia - pain from stimuli that normally don't cause pain (such as light touch) 1
  • Hyperalgesia - exaggerated pain response to painful stimuli 1
  • Burning pain particularly affecting feet and hands, characteristic of small fiber neuropathy from agents like vinca alkaloids, taxanes, thalidomide, and bortezomib 1
  • Lancinating pain that can be easily potentiated by pin-prick testing 1

"Minus" Symptoms (Diminished Pain Sensation)

Paradoxically, neurotoxicity also causes sensory loss in affected areas:

  • Hypoalgesia - decreased pain perception to pin prick testing 1
  • Decreased temperature sensation in painful areas, particularly with small fiber neuropathy 1
  • Numbness in a "glove and stocking" distribution affecting hands and feet 1, 2
  • Impaired perception of light touch, vibration sense, and proprioception 1, 2

Mechanism-Based Pain Patterns

Large Fiber Involvement

When large sensory nerves are affected by neurotoxic agents (most common pattern):

  • Symmetrical, length-dependent "dying back axonopathy" occurs 1
  • Predominantly sensory symptoms with glove-and-stocking distribution 1, 3
  • Loss of vibration sense and proprioception predominate 1

Small Fiber Neuropathy

When nerve terminals involved in temperature and pain perception are affected:

  • Burning feet syndrome (and/or hands) is the classic presentation 1
  • Decreased pain and temperature sensation occurs paradoxically in the painful areas 1
  • Common with vinca alkaloids, taxanes, thalidomide, and bortezomib 1

Sensory Ganglionopathy

With platinum compounds, vinca alkaloids, taxanes, and thalidomide:

  • Dorsal root ganglion cell bodies are directly damaged due to less protective blood-brain barrier 1
  • Clinical picture may be asymmetrical (unlike typical length-dependent patterns) 1
  • Predominantly involves proprioception but can affect motor systems 1
  • Often irreversible damage 1

Clinical Implications

The altered pain sensation in neurotoxicity is clinically significant because:

  • It affects approximately 70% of patients receiving neurotoxic chemotherapy 4
  • Pain symptoms can persist lifelong in 15-40% of patients after platinum-based treatment completion 3
  • These sensory alterations significantly reduce quality of life and may necessitate dose reduction or treatment interruption 5, 4
  • The coexistence of both heightened and diminished pain perception in the same patient is characteristic and helps distinguish neurotoxic neuropathy from other causes 1

Critical Pitfall

Do not dismiss patient reports of pain in areas where they also describe numbness - this paradoxical combination of "plus" and "minus" symptoms is pathognomonic for neurotoxic neuropathy, particularly small fiber involvement. 1 The decreased pain perception on examination does not negate the reality of their neuropathic pain symptoms.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Agent Orange and Peripheral Neuropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Platinum-Based Chemotherapy-Induced Peripheral Neuropathy Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Neuropathic pain caused by the toxic effect of chemotherapy in patients with malignant neoplasms].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023

Research

Mechanisms of Chemotherapy-Induced Neurotoxicity.

Frontiers in pharmacology, 2022

Related Questions

I experience a sensation of walking on a slope, especially during long distances, after completing chemotherapy treatment with polatuzumab (Polatuzumab Vedotin) - rituximab (Rituxan) - cyclophosphamide (Cytoxan) - doxorubicin (Adriamycin) - prednisone for lymphoma, could this be a side effect of the treatment?
How can a patient with a history of cancer treatment, specifically chemotherapy for brain tumors, develop neuropathy without having diabetes?
What causes numbness after an intramuscular injection?
What is the best approach to manage chemotherapy-induced neuropathic pain in a patient with a history of platinum-based treatment?
What is the best treatment option for a patient with otitis media who is allergic to amoxicillin (a type of penicillin antibiotic)?
What is the recommended treatment with oral steroids for a patient presenting with back pain, considering potential comorbidities such as diabetes, hypertension, or osteoporosis?
What are the indications for bone densitometry in patients with risk factors for osteoporosis, such as postmenopausal women, older adults, and those with a history of fractures or certain medical conditions like rheumatoid arthritis or thyroid disorders?
Does Proventil (albuterol) come in a higher dose than 5 mg per 3 mL inhalation solution?
Do individuals with a history of hepatitis B (HB) vaccination require a booster dose after a needle stick exposure?
What is the best management plan for a 16-year-old female patient with Ehlers-Danlos hypermobility, presenting with leukopenia, hyperferritinemia, and low alkaline phosphatase, given her recent lab results?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.